This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop an optimized hardware and bioware kit for a shell-free quail xenograft assay. This assay aims to "preview" animal studies and identify the most promising drug compounds for preclinical research, thereby reducing the high costs and failure rates typically associated with pharmaceutical drug development. The key products to be delivered include:
-
Refinement and testing of a hardware product line for the quail xenograft assay, optimizing throughput and durability using environmentally-friendly materials.
-
Development and testing of a prototype bioware kit with shipping-safe packaging and a simplified assay protocol, benchmarking reproducibility and throughput for experienced and beginner users.
Upon completion of these proof-of-concept milestones, the goal is to bring the optimized assay kit for beta-testing in early pharmaceutical R&D labs investigating new cancer therapeutics, with the potential to significantly streamline and improve the efficiency of the drug development process.
Generated 1/28/25, 10:15 AM